News Conference News Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality Michael O'Riordan March 22, 2024
News Daily News One in Three Overweight MI Patients May Benefit From Semaglutide Todd Neale February 26, 2024
News Daily News BP Reductions Last 5 Years After Bariatric Surgery: GATEWAY Michael O'Riordan February 07, 2024
News Daily News Universal Risk Tool Works Well in Both Primary and Secondary Prevention Michael O'Riordan February 01, 2024
News Daily News Top General Cardiology and CVD Prevention News of 2023 Yael L. Maxwell January 03, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for December 2023 Caitlin E. Cox December 28, 2023
News Daily News Who Benefits Most From Semaglutide and How Long Will That Take? Shelley Wood December 19, 2023
News Daily News Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk Todd Neale December 12, 2023
News Daily News ‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults Michael O'Riordan November 21, 2023
News Daily News Mortality Risk Varies Among Patients With Very High LDL Levels Michael O'Riordan November 17, 2023
News Conference News AHA 2023 New CVD Risk Tool Can Spur Even Earlier Talk About Prevention Yael L. Maxwell November 14, 2023
News Conference News AHA 2023 Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics Todd Neale November 11, 2023
News Daily News Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study L.A. McKeown October 10, 2023
News Daily News Major GI Events Rare but Real in Weight-Loss Patients on GLP-1 Drugs Caitlin E. Cox October 06, 2023
News Daily News Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle Todd Neale September 12, 2023
News Daily News Mortality, CVD Benefits Seen at Relatively Low Daily Step Counts Michael O'Riordan September 08, 2023